UniQure has posted fresh data from a phase 1/2 trial of its hemophilia B gene therapy. The 12-month low-dose data and six-month high-dose results link AMT-060 to the near-cessation of spontaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results